Astria Therapeutics, Inc.
General ticker "ATXS" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $507.0M (TTM average)
Astria Therapeutics, Inc. follows the US Stock Market performance with the rate: 19.9%.
Estimated limits based on current volatility of 5.0%: low 4.85$, high 5.37$
Factors to consider:
- Earnings expected soon, date: 2025-05-08 bmo
- Price in estimated range
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [3.58$, 10.64$]
- 2025-12-31 to 2026-12-31 estimated range: [2.79$, 8.22$]
Financial Metrics affecting the ATXS estimates:
- Negative: Non-GAAP EPS, $ of -1.67 <= 0.04
- Negative: negative Net income
- Negative: Operating cash flow per share per price, % of -12.67 <= 1.79
- Negative: negative Operating income
- Positive: Interest expense per share, $ of 0 <= 0
Short-term ATXS quotes
Long-term ATXS plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
| Operating Expenses | $53.50MM | $83.03MM | $111.56MM |
| Operating Income | $-53.50MM | $-83.03MM | $-111.56MM |
| Non-Operating Income | $1.67MM | $10.14MM | $17.30MM |
| R&D Expense | $34.26MM | $57.33MM | $77.11MM |
| Income(Loss) | $-51.83MM | $-72.89MM | $-94.26MM |
| Profit(Loss)* | $-50.16MM | $-72.89MM | $-94.26MM |
| Stockholders Equity | $221.22MM | $243.12MM | $319.26MM |
| Assets | $230.63MM | $254.67MM | $342.36MM |
| Operating Cash Flow | $-43.53MM | $-68.44MM | $-81.21MM |
| Capital expenditure | $0.09MM | $0.03MM | $0.33MM |
| Investing Cash Flow | $-167.13MM | $135.05MM | $-191.86MM |
| Financing Cash Flow | $144.72MM | $88.40MM | $157.20MM |
| Earnings Per Share** | $-3.43 | $-2.42 | $-1.67 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.